Kidney transplant recipients develop disorders of mineral and bone metabolism that further impair bone strength, leading to osteoporosis and a high fracture risk. However, evidence in this setting is limited. Romosozumab, a sclerostin inhibitor with both anabolic and antiresorptive effects, is an attractive option, but...
Simona Barbuto, Paolo Mastromauro, G. Zavatta et al.· Frontiers in Endocrinology· 0 citations
Background. Older adults represent a growing proportion of kidney transplant (KT) recipients, but early posttransplant morbidity remains substantial. We aimed to identify pretransplant factors associated with a complicated early posttransplant course in recipients aged ≥65 y and to assess its impact on subsequent outco...
D. Vetrano, E. Gessaroli, V. Corradetti et al.· Transplantation Direct· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.